β-Arrestin–biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor–targeting antibodies in Ewing’s sarcoma

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 50, 2012, Pages 20620-20625

  Zheng, Huiyuan ^a   Shen, Hongchang ^a,b   Oprea, Iulian ^a   Worrall, Claire ^a   Stefanescu, Radu ^a   Girnita, Ada ^a   Girnita, Leonard ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Arrestin2; Functional selectivity; GPCR; Internalization; RTK; Trafficking

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; BETA ARRESTIN; BETA ARRESTIN 1; FIGITUMUMAB; SOMATOMEDIN C RECEPTOR; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; RETINA S ANTIGEN; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; EWING SARCOMA; EWING SARCOMA CELL LINE; LIGAND BINDING; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECEPTOR DOWN REGULATION; UBIQUITINATION; WESTERN BLOTTING; DOWN REGULATION; DRUG ANTAGONISM; DRUG POTENTIATION; GENE INACTIVATION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ARRESTINS; BASE SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; GENE KNOCKOUT TECHNIQUES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MAP KINASE SIGNALING SYSTEM; RECEPTOR, IGF TYPE 1; RNA, SMALL INTERFERING; SARCOMA, EWING; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 84874417600     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1216348110     Document Type: Article

References (43)

1. Sell C, et al. (1994) Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 14(6): 3604–3612.
2. Baserga R, Peruzzi F, Reiss K (2003) The IGF-1 receptor in cancer biology. Int J Cancer 107(6):873–877.
3. Economou MA, et al. (2008) Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor. Invest Ophthalmol Vis Sci 49(6):2620–2626.
4. Yin S, et al. (2010) Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. Neuro-oncol 12(1):19–27.
5. Vasilcanu D, et al. (2006) The insulin-like growth factor-1 receptor inhibitor PPP produces only very limited resistance in tumor cells exposed to long-term selection. Oncogene 25(22):3186–3195.
6. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8(12):915–928.
7. Gualberto A, Pollak M (2009) Emerging role of insulin-like growth factor receptor inhibitors in oncology: Early clinical trial results and future directions. Oncogene 28 (34):3009–3021.
8. Pollak M (2012) The insulin and insulin-like growth factor receptor family in neoplasia: An update. Nat Rev Cancer 12(3):159–169.
9. Olmos D, et al. (2011) Targeting the insulin-like growth factor 1 receptor in Ewing’s sarcoma: Reality and expectations. Sarcoma 2011:402508.
10. Olmos D, et al. (2010) Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing’s sarcoma: A phase 1 expansion cohort study. Lancet Oncol 11(2):129–135.
11. Juergens H, et al. (2011) Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol 29(34):4534–4540.
12. Corral J, López-Villalobos JL, Gomez-Izquierdo L, Borrego I, Paz-Ares L (2011) Path-ologic complete responses after chemotherapy plus figitumumab in stage IV non-small-cell lung cancer. J Clin Oncol 29(7):e163–e165.
13. Toretsky JA, Kalebic T, Blakesley V, LeRoith D, Helman LJ (1997) The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 272(49):30822–30827.
14. Girnita L, et al. (2000) Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing’s sarcoma cells: therapeutic implications. Anticancer Drug Des 15(1):67–72.
15. Girnita A, et al. (2004) Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 64(1):236–242.
16. Wang M, et al. (1999) Regulatory role of mevalonate and N-linked glycosylation in proliferation and expression of the EWS/FLI-1 fusion protein in Ewing’s sarcoma cells. Exp Cell Res 246(1):38–46.
17. McKinsey EL, et al. (2011) A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs. Oncogene 30(49): 4910–4920.
18. Baserga R (2005) The insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opin Ther Targets 9(4):753–768.
19. Cohen BD, et al. (2005) Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11(5):2063–2073.
20. Garofalo C, et al. (2011) Efficacy of and resistance to anti-IGF-1R therapies in Ewing’s sarcoma is dependent on insulin receptor signaling. Oncogene 30(24):2730–2740.
21. Girnita L, Girnita A, Larsson O (2003) Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor. Proc Natl Acad Sci USA 100(14): 8247–8252.
22. Vecchione A, Marchese A, Henry P, Rotin D, Morrione A (2003) The Grb10/Nedd4 complex regulates ligand-induced ubiquitination and stability of the insulin-like growth factor I receptor. Mol Cell Biol 23(9):3363–3372.
23. Sehat B, Andersson S, Vasilcanu R, Girnita L, Larsson O (2007) Role of ubiquitination in IGF-1 receptor signaling and degradation. PLoS ONE 2(4):e340.
24. Shenoy SK, Lefkowitz RJ (2011) β-Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol Sci 32(9):521–533.
25. Shukla AK, Xiao K, Lefkowitz RJ (2011) Emerging paradigms of β-arrestin-dependent seven transmembrane receptor signaling. Trends Biochem Sci 36(9):457–469.
26. Rajagopal S, Rajagopal K, Lefkowitz RJ (2010) Teaching old receptors new tricks: Biasing seven-transmembrane receptors. Nat Rev Drug Discov 9(5):373–386.
27. Reiter E, Ahn S, Shukla AK, Lefkowitz RJ (2012) Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol 52: 179–197.
28. Benini S, et al. (2004) Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing’s sarcoma cells: Therapeutic prospects. Int J Cancer 108 (3):358–366.
29. Scotlandi K, et al. (1996) Insulin-like growth factor I receptor-mediated circuit in Ewing’s sarcoma/peripheral neuroectodermal tumor: A possible therapeutic target. Cancer Res 56(20):4570–4574.
30. Sehat B, Andersson S, Girnita L, Larsson O (2008) Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis. Cancer Res 68(14):5669–5677.
31. Girnita L, et al. (2005) beta-Arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase. J Biol Chem 280(26):24412–24419.
32. Girnita L, et al. (2007) Beta-arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression. J Biol Chem 282(15):11329–11338.
33. Attias-Geva Z, et al. (2011) Insulin-like growth factor-I receptor (IGF-IR) targeting with monoclonal antibody cixutumumab (IMC-A12) inhibits IGF-I action in endometrial cancer cells. Eur J Cancer 47(11):1717–1726.
34. Broussas M, et al. (2009) Molecular mechanisms involved in activity of h7C10, a humanized monoclonal antibody, to IGF-1 receptor. Int J Cancer 124(10):2281–2293.
35. Mao YF, et al. (2011) Polyubiquitination of insulin-like growth factor I receptor (IGF-IR) activation loop promotes antibody-induced receptor internalization and downregulation. J Biol Chem 286(48):41852–41861.
36. Pandini G, et al. (2007) Functional responses and in vivo anti-tumour activity of h7C10: A humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur J Cancer 43(8): 1318–1327.
37. Nobles KN, et al. (2011) Distinct phosphorylation sites on the β(2)-adrenergic receptor establish a barcode that encodes differential functions of β-arrestin. Sci Signal 4(185): ra51.
38. Rajagopal S, et al. (2011) Quantifying ligand bias at seven-transmembrane receptors. Mol Pharmacol 80(3):367–377.
39. Vasilcanu R, et al. (2008) Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-ar-restin1. Oncogene 27(11):1629–1638.
40. Vasilcanu R, et al. (2008) Insulin-like growth factor type-I receptor-dependent phosphorylation of extracellular signal-regulated kinase 1/2 but not Akt (protein kinase B) can be induced by picropodophyllin. Mol Pharmacol 73(3):930–939.
41. Vitale M, et al. (2008) New picropodophyllin analogs via palladium-catalyzed allylic alkylation-Hiyama cross-coupling sequences. J Org Chem 73(15):5795–5805.
42. Girnita A, Zheng H, Grönberg A, Girnita L, Ståhle M (2012) Identification of the cathelicidin peptide LL-37 as agonist for the type I insulin-like growth factor receptor. Oncogene 31:352–365.
43. Zheng H, et al. (2012) Selective recruitment of G protein-coupled receptor kinases (GRKs) controls signaling of the insulin-like growth factor 1 receptor. Proc Natl Acad Sci USA 109(18):7055–7060.